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ABSTRACT
Bone metastases are one of the main complications of prostate cancer and they 
are incurable. We investigated whether and how estrogen receptor-related receptor 
alpha (ERRα) is involved in bone tumor progression associated with advanced prostate 
cancer. By meta-analysis, we first found that ERRα expression is correlated with 
castration-resistant prostate cancer (CRPC), the hallmark of progressive disease. We 
then analyzed tumor cell progression and the associated signaling pathways in gain-of-
function/loss-of-function CRPC models in vivo and in vitro. Increased levels of ERRα in 
tumor cells led to rapid tumor progression, with both bone destruction and formation, 
and direct impacts on osteoclasts and osteoblasts. VEGF-A, WNT5A and TGFβ1 were 
upregulated by ERRα in tumor cells and all of these factors also significantly and 
positively correlated with ERRα expression in CRPC patient specimens. Finally, high 
levels of ERRα in tumor cells stimulated the pro-metastatic factor periostin expression 
in the stroma, suggesting that ERRα regulates the tumor stromal cell microenvironment 
to enhance tumor progression. Taken together, our data demonstrate that ERRα is a 
regulator of CRPC cell progression in bone. Therefore, inhibiting ERRα may constitute 
a new therapeutic strategy for prostate cancer skeletal-related events. 
INTRODUCTION
Bone metastases are a frequent complication of 
cancer occurring in up to 80% of patients with advanced 
prostate cancer (PCa) and castration-resistance (CRPC 
“castration-resistant prostate cancer”) with associated 
poor five-year survival rate [1, 2]. They are not curable 
and result in impaired mobility and pathological 
fractures [3]. To grow in bone, tumor cells alter bone 
formation and resorption by secreting proteins that 
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directly affect osteoblasts (bone-forming cells) and 
osteoclasts (bone-resorbing cells) resulting in the 
development of mixed lesions [1, 4]. These signaling 
proteins may include RANKL (receptor activator 
of the NF-kB ligand) which stimulates osteoclast 
differentiation [1, 5] and osteoprotegerin (OPG) which 
acts as a decoy receptor for RANKL receptor and inhibits 
osteoclastogenesis [5]. Therefore, the balance between 
RANKL and OPG is critical in controlling osteoclast 
activity and osteolysis in bone metastases. PCa cells 
also express factors such as TGFβ (transforming growth 
factor beta), WNT family members such as Wnt5a 
and the pro-angiogenic factor VEGFA that promote an 
aggressive tumor phenotype and bone metastases by 
directly affecting osteoclast and osteoblast formation 
[6, 7]. The induction of stromal niche signals by tumor 
cells, for example expression of extracellular matrix 
proteins such as PERIOSTIN (POSTN) in the tumor 
microenvironment, also contributes to the expansion of 
the metastatic niches [8–11]. 
Nuclear receptors are transcription factors that 
comprise ligand-dependent molecules, such as estrogen 
receptors (ERs), and a large number of so-called orphan 
receptors for which no ligand has yet been determined 
[12]. Estrogen receptor-related receptor alpha (ERRα)
(NR3B1) shares structural similarities with ERα and 
ERβ (NR3A1/NR3A2) [13] but does not bind estrogen 
[14]. Since very recently, ERRα was considering as the 
oldest orphan receptor but Wei et al. just described the 
cholesterol as a potential ERRα agonist [15]. Synthetic 
molecules like the inverse agonist XCT-790 were 
also designed to block ERRα activity by preventing 
its interaction with the co-activators peroxisome 
proliferator-activated receptor gamma coactivator 
(PGC1) [16]. 
ERRα is expressed in a range of cancer cell types 
and ERRα-positive tumors (breast and prostate) are 
associated with more invasive disease and higher risk 
of recurrence [17, 18]. Indeed in prostate cancer, ERRα 
is significantly higher in cancerous lesions compared 
to benign foci and high level of ERRα correlates with 
Gleason score and poor survival [18]. Moreover, in 
androgen receptor (AR)-positive models, ERRα has 
been implicated in AR signaling pathways and shown to 
increase HIF-1 signaling and to promote hypoxic growth 
adaptation of prostate cancer cells [19, 20]. ERRα is also 
expressed in bone where it regulates differentiation and 
activity of osteoblasts and osteoclasts, both of which 
are implicated into the mixed osteolytic and osteoblastic 
lesions observed in advanced prostate cancer patients [15] 
[21]. Based on our previous data in bone metastases from 
breast cancer [22], and on the fact that bone metastases 
are the hallmark of progressive disease and CRPC, mainly 
characterized by AR alterations [23], we investigated 
whether and how ERRα is involved in bone progression 
of CRPC (AR-negative) models.
RESULTS 
ERRα is more highly expressed in CRPC 
patients and their associated bone metastases 
than normal prostate and non-metastasizing PCa
To determine whether ERRα is involved in 
PCa bone lesions, we first assessed ERRα mRNA 
expression (ESRRA) levels during disease progression 
by performing a meta-analysis of data from the gene 
expression omnibus (GEO; GSE69129, GSE21034 
and GSE32269) (Figure 1A–1C, Supplementary Table 
S1)[24, 25, 26]. We found that ERRα expression was 
significantly higher in CRPC compared to normal 
prostate (P = 0.0172)(Figure 1A) and (P = < 0.05, n 
= 22 (normal) vs n = 41 (CRPC)) (Figure 1B). Higher 
ERRα expression was also observed in primary 
tumors from CRPC patients who had developed bone 
metastases compared to androgen-sensitive PCa patients 
(P < 0.005, (PCa) vs (CRPC bone Mets))(Figure 1B) and 
(P = 0.0178, (PCa) vs (CRPC who all developed bone 
metastases)) (Figure 1C). In the dataset GSE21034, we 
also found that ERRα mRNA was significantly higher 
in primary cancerous prostate lesions from CRPC who 
developed bone metastatic lesions (n = 5) compared to 
patients with had developed other types of metastases 
(brain, lung, bladder, colon or lymph nodes) (n = 41) 
(P < 0.05; Figure 1B) suggesting that ERRα is associated 
with advanced prostate cancer and bone metastases. 
Immunohistochemistry also revealed that ERRα protein 
expression in human PCa cells was maintained in the 
associated bone metastases (Figure 1D), suggesting 
that ERRα is an overall poor prognostic factor for bone 
metastases from CRPC. 
ERRα in PCa cells promotes tumor cells 
progression in vivo in bone microenvironment
To address ERRα function in PCa bone progression, 
we used three CRPC pre-clinical models, two human 
models (PC3 and PC3c) and one canine model (ACE-1). 
Specifically, a full-length ERRα cDNA was stably 
transfected into PC3 cells, which are known for their 
capacity to form osteolytic lesions in vivo [27]. Three 
independent PC3-ERRα clones (overexpressing ERRα) 
and three PC3-CT clones (harboring empty vector) were 
generated (Figure 1E, 1F). In parallel, to validate further 
the human PC3 model, human PC3c and canine ACE-1 
PCa cells that both induce mixed bone lesions (with both 
osteolysis and osteoformation) were stably transfected 
with full-length ERRα cDNA (Figure 1H, 1J) [28] [29]. 
ACE-1 cells were also transfected with cDNA containing 
a truncated form of ERRα lacking the co-activator binding 
domain AF2 (AF2) (Figure 1J) [22]. Western blotting 
confirmed higher ERRα expression in PC3-ERRα, PC3c-
ERRα and ACE-1-ERRα than in their respective control 
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cells (Figure 1E, 1H, 1J). The presence of a slightly lower 
molecular weight band in AF2 in ACE-1 cells expressing 
the ERRα-AF2 deletion mutant corresponded well with its 
expected smaller size (AF2; Figure 1J) [22]. As expected, 
expression of mRNA for VEGF-A, a known ERRα target 
gene [30] was higher in all of the ERRα overexpressing 
clones (ERRα; PC3, PC3c and ACE-1) but not in the AF2 
ACE-1 clone, confirming the increased activity and the 
dominant negative functions of both wild-type ERRα and 
the truncated ERRα-AF2 constructs respectively (Figure 
1G, 1I, 1K). To assess whether and how levels of ERRα 
in tumor cells affected progression of bone lesions, 
PC3, PC3c and ACE-1 clones were inoculated via intra-
tibial injections into SCID male mice (Figure  2). Three 
weeks (for PC3 (pool of the 3 clones for CT and ERRα 
respectively) and ACE-1 clones) (Figure 2 (PC3 (A–E), 
ACE-1 (K–Q)) and six weeks (for PC3c clones) (Figure 2 
PC3c (F–J)) after tumor cell injections, radiographs 
revealed that animals bearing ERRα overexpressing 
tumors had increased bone lesion surfaces whereas ACE-
AF2 tumors had decreased bone lesion surface compared 
to CT tumors (Figure 2 -PC3 (A–B), (Mann-Whitney, 
P = 0.011) (bone lesion surface mm2)(E), -PC3c (F-G), 
(Mann-Whitney, P = 0.0175)(J) -ACE-1 (K–M) (Mann-
Whitney, P = 0.0079, P = 0.0304) (Q)). The stimulatory 
effect of ERRα on PCa-induced bone lesion surface 
was confirmed by three-dimensional micro-computed 
tomographic reconstruction (%BV/TV) (cortical and 
Figure 1: ERRα expression and CRPC from PCa patients. (A) Meta-analysis using public datasets showed that ERRα mRNA 
expression is higher in CRPC patients in GSE6919 (Student’s t-test P = 0.0172). (B) ERRα was also found to be higher in CRPC compared 
to androgen-sensitive PCa, as well as in primary tumors from CRPC patients that developed metastases to bone compared to other sites or 
normal prostate tissues in GSE21034 (One way ANOVA, bonferri post-hoc test : P < 0,05, normal (n = 22) versus CRPC (n = 41); P < 0.0005, 
normal (n = 22) versus CRPC bone mets (n = 5); P < 0.005, PCa (n = 104) versus CRPC bone mets (n = 5)) and (C) PCa versus CRPC (that 
all had developed bone metastases) in GSE32269 (Student’s t-test P = 0.0178): *P < 0.05, **P < 0.005, ***P < 0.0005. (D) Visualization 
of ERRα protein expression by IHC on sections of prostate primary tumor (a) and the associated bone metastatic lesions (b) from the same 
patient. (E) Assessment of ERRα expression by Western blotting and (F) real-time RT-PCR on triplicate samples and normalized against the 
ribosomal protein gene L32 (ANOVA, Student’s t-tests P < 0.0001) in PC3 control (CT-1-3) and PC3-ERRα (ERRα-1–3) overexpressing 
ERRα clones. (G) Increased expression of VEGF-A mRNA in PC3-ERRα (ANOVA, Student’s t-tests P < 0.0001). (H) Increase of ERRα 
protein expression in PC3c-ERRα (ERRα(c)) overexpressing ERRα shown by Western blot and (I) by real-time RT-PCR for VEGF-A 
expression (Student’s t-tests P = 0.001). (J) Assessment of ERRα expression by Western blotting in an ACE-1 empty-vector CT clone, an 
ACE-ERRα and a clone overexpressing the dominant negative ERRα with AF2 domain deletion (AF2). (K) VEGF-A mRNA expression was 
also increased in ACE-ERRα cells (Student’s t-tests P = 0.0001). Bar = 200 μm, T: Tumor; Ost: osteocytes; BM: Bone Matrix
Oncotarget77074www.impactjournals.com/oncotarget
trabecular bone), with a decrease in bone volume in 
animals bearing PC3-ERRα and ACE-1-ERRα tumors 
(%BV/TV, Mann-Whitney, PC3 P = 0.022 and, ACE-1 
P = 0.0411) suggesting an increase in bone destruction 
in both ERRα overexpression models (Figure 2E and 
2Q, %BV/TV). The stimulatory effect of ERRα on PCa-
induced bone lesion surface was also evident by histology 
(Figure 2 PC3(C,D)) and histomorphometric analysis (TB/
STV) with an increase of skeletal tumor burden (Figure 2E 
and 2Q). Since the osteoblastic region is highly stimulated 
in the PC3c model (Figure 2H, 2I) (see the increased of 
the %BV/TV: (Mann-Whitney, P = 0.022)), the surface of 
the tumor (TB/STV) decreased in animals bearing PC3c-
ERRα (Figure 2J (Mann-Whitney, P = 0.0023)) (asterisks 
showing bone formation). Similarly, 70% of mice bearing 
PC3-ERRα tumors exhibited small new bone formation 
compared to mice bearing PC3-CT tumors (Figure 2E). 
New bone formation was also seen in animals bearing 
ACE-1-ERRα versus ACE-1-CT tumors (Figure 2Q: 
extra-bone-new spicules surface formation/ tissue volume; 
Figure 2 (N-P) (asterisks mark extra-new spicules bone 
formation). The bone lesion surface and bone volume-new 
Figure 2: Over-expression of ERRα in prostate cancer cells induced bone lesions development. Radiography revealed larger 
lesions in mice injected with (A, B) PC3-ERRα versus PC3-CT, and (F, G) with PC3c-ERRα versus PC3c-CT. Histology after Goldner’s 
trichrome staining confirmed the radiography results in mice injected with (C, D) PC3-ERRα versus PC3-CT (H, I) with PC3c-ERRα versus 
PC3c-CT (bone matrix in green). (E) Induction -of larger bone lesions surface in mice injected with PC3-ERRα (ERRα)(Mann-Whitney, 
P = 0.011), -of a decrease in %BV/TV (Mann-Whitney, P = 0.022) and an increase of %TB/STV (Mann-Whitney, P = 0.008) compared 
with mice injected with PC3-CT (CT). Bone formation incidence show that 70% of mice injected with PC3-ERRα (ERRα) developed 
some bone formation as opposed to 10% of mice injected with PC3-CT (CT). (J) Increased -of bone lesions surface in mice injected with 
PC3c-ERRα (Mann-Whitney, P = 0.0175), -of the %BV/TV (Mann-Whitney, P = 0.022) and decrease of the %TB/STV (Mann-Whitney, 
P = 0.0023) compared with mice injected with PC3c-CT (CT). Radiography (K–M) and 3D micro-tomography reconstructions (N–P) 
showed larger bone lesions in mice injected with ACE-ERRα versus ACE-CT with an abrogation of the bone lesion effects seen with ERRα 
overexpression in tumors bearing the dominant negative AF2-truncated ERRα. (Q) After 3 weeks post inoculation of ACE-ERRα, ACE-
CT and ACE-AF2 cells, radiography revealed larger and smaller bone lesions surface in mice injected with ACE-ERRα and ACE-AF2 
respectively compared to CT (Mann-Whitney, P = 0.0079, P = 0.0304) and microtomographic reconstructions of tibiae show a decrease in 
mice injected with ACE-ERRα compared to CT (%BV/TV: Mann-Whitney, P = 0.0411), an increase in %TB/STV (Wilcoxon, P = 0.034) 
compared to CT, and an increase in % new bone formation/TV (extra-bone spicules formation): (Mann-Whitney, P = 0.0025). The increase 
in bone lesion surface (Mann-Whitney, P = 0.0011), in the %TB/STV (Mann-Whitney, P = 0.0052), in the extra-bone spicules formation 
(Mann-Whitney, P = 0.0012) and the decrease in %BV/TV (Wilcoxon, P = 0.0273) effects seen with ERRα overexpression were markedly 
abrogated in tumors bearing the dominant negative AF2-truncated ERRα. * = P < 0.05; ** = P < 0.001; *** = P < 0.0001. T: Tumor; 
* bone formation; Arrow: bone degradation.
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bone formation effects seen with ERRα overexpression 
were markedly abrogated in tumors bearing the dominant 
negative AF2-truncated ERRα (Figure 2K, 2M and 2N, 2P, 
2Q). Taken together, our results indicate that overexpression 
of ERRα in PCa cells stimulates both new bone formation 
and destruction suggesting that it may be associated with 
mechanisms mediating mixed lesions in vivo. 
Modulation of ERRα expression in cancer cells 
affects the bone microenvironment
Since our in vivo data suggested an impact of ERRα 
expression levels on PCa-induced bone destruction and 
formation, we next assessed whether PCa overexpressing 
ERRα cells affected osteoclasts (bone-resorbing cells) 
and osteoblasts (bone-forming cells). A 40% increase in 
TRAP-positive osteoclast surface (%Oc.S/BS) was seen 
at the bone-tumor cell interface in PC3-ERRα tumors 
(Figure 3A). Consistent with these in vivo data, the number 
of TRAP-positive cells (Figure 3B) and the expression of 
osteoclast markers (trap, ck, caII and rank) (Figure 3C) 
were higher in co-cultures of primary mouse bone marrow 
cells with PC3-ERRα cells compared to PC3-CT cells 
[5]. Moreover, treatment of bone marrow cells by the 
conditioned medium obtained from parental PC3 cells 
treated with the inverse agonist XCT-790, which blocks 
ERRα activity, inhibited osteoclast formation (Figure 3D). 
Similarly, PC3c- ERRα cells co-cultured with primary 
mouse bone marrow cells also stimulated osteoclast 
formation compared to PC3c-CT cells (Figure 3E), as 
did ACE-1-ERRα compared to ACE-1-CT cells while 
ACE-1-AF2 inhibited osteoclastogenesis compared to 
ACE-1-ERRα (Figure 3F) suggesting that cancerous cells 
expressing ERRα increase osteoclastogenesis. 
The increased bone formation observed in vivo 
suggests that changes in ERRα expression in PCa cells 
also alters the differentiation of osteoblasts. Consistent 
with this hypothesis, a higher number of bone nodules 
formed in primary mouse calvaria cells cultured with PC3-
ERRα versus PC3-CT conditioned medium (Figure 4A). 
Similarly, the expression of the osteoblastic markers 
alkaline phosphatase (alp), bone sialoprotein (bsp) and 
osteocalcin (ocn) increased (Figure 4C) in co-cultures 
of MC3T3-E1 and PC3-ERRα cells (ERRα) (Figure 4C)
[31]. The pro-osteoclastic factors rankl but not opg, was 
increased in MC3T3-E1 cells co-cultured with PC3-ERRα 
Figure 3: ERRα overexpression in PCa-ERRα cells modified bone-resorbing cells. (A) Increase in osteoclast (Oc) surface in 
bone lesions induced by PC3-ERRα cells in vivo (%Oc.S/BS: Mann-Whitney, P = 0.0062; n = 7 (CT) and n = 10 (ERRα)). (B) PC3-ERRα 
cells increase the number of TRAP+ osteoclasts in vitro (Oc number/well: paired t-test, P = 0.0275). (C) mRNA was extracted from co-
cultures on day 7. The expression of trap (Tartrate Resistant Acid Phosphatase), ck (Cathepsin K), rank and caII (Carbonic Anhydrase II) 
was assessed by real-time RT-PCR on triplicate samples; all markers were higher in Oc/PC3-ERRα (ERRα) versus Oc/PC3-CT (Student’s 
t-tests, P = 0.0026; P = 0.0055, P = 0.0057; P = 0.008). (D) Conditioned medium obtained from parental PC3 cells treated with the inverse 
agonist XCT-790 decreased Oc formation, confirming the results obtained with PC3-ERRα (Student’s t-tests, P = 0.0023). (E–F) PC3c-
ERRα (E) and ACE-ERRα (F) increased the number of TRAP+ osteoclasts in vitro compared to the respective controls (Oc number/well: 
paired t-test, P = 0.022 (PC3c-ERRα versus PC3C-CT) and ANOVA p = 0.0048, P < 0.05 (ACE-1-ERRα versus ACE-1-CT) while ACE-1-
AF2 inhibited Oc formation P < 0.005 (ACE-1-AF2 versus ACE-1-ERRα). Oc results are representative of two independent experiments, 
each performed in triplicate samples.
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cells (Figure 4D). Consistent with this, we observed a 
trend towards an increase in the number of bone nodules 
formed in primary mouse calvaria cells cultured with 
PC3c-ERRα conditioned medium (Figure 4B) and an 
increase in osteoblastic markers bsp and ocn expression 
in co-cultures of MC3T3-E1 and ACE-1-ERRα cells 
(ERRα) (Figure 4E). In contrast, no change in expression 
of either osteoblastic markers was detected in co-cultures 
of MC3T3-E1 with ACE-1-AF2 cells (Figure 4E). Also 
no regulation of rankl and opg expression was noticed 
(Figure 4F). Taken together, our results suggest that ERRα 
expression in PCa cells induces changes in osteoblast 
lineage cells. 
Identification of two factors regulated in PCa 
cells that couple bone resorption and formation: 
VEGFA and Wnt5a 
Since both osteoclasts and osteoblasts are stimulated 
by PCa cells overexpressing ERRα, we next sought to 
identify factors secreted by PCa cells that may stimulate 
both lineages. As shown earlier, PC3, PC3c and ACE-1 
cells overexpressing ERRα stimulate expression of 
VEGF-A (Figure 1G, I, K), a known ERRα target and 
stimulator of osteoblasts and osteoclasts [32, 33]. By 
immunohistochemistry, ERRα (Figure 5A, 5B) and 
VEGF-A (Figure 5C, 5D) expression was observed in PCa 
cells and higher in PC3-ERRα-induced bone lesions in vivo 
(Figure 5B and 5D respectively) compared to PC3-CT 
lesions (Figure 5A and 5C respectively). Regulation of 
VEGF-A by ERRα was confirmed in vitro in PC3 cells 
transfected with a pool of three ERRα-siRNA sequences 
(Si) compared to control sequences (Sc) (Figure 5E–5G). 
Blocking ERRα activity by treating PC3-ERRα cells with 
the ERRα inverse agonist XCT-790 also demonstrated 
a statistical down-regulation of VEGF-A (Figure 5H). 
That ERRα regulates VEGF-A in both non-bone and 
bone microenvironments was determined by assessing 
subcutaneous (SC) tumors obtained by injecting PC3-ERRα 
and PC3-CT clones in male SCID mice. VEGF-A expression 
was higher in PC3-ERRα (ERRα) -tumors compared to 
PC3-CT (CT)-induced SC tumors in vivo (Figure 5I–5J). 
The correlation of increased ERRα and increased VEGF-A 
expression was confirmed in PC3c-ERRα-induced bone 
Figure 4: ERRα overexpression in PCa-ERRα cells stimulates bone-forming cells. (A) Osteoblasts (Ob) from primary mouse 
calvaria cell cultures were treated with conditioned medium of PC3-ERRα (ERRα) or PC3-CT (CT) cells. Bone nodule number was higher 
in co-cultures with PC3-overexpressing ERRα (Ob-ERRα) (Mann-Whitney, P = 0.0118). (B) When treated with conditioned medium of 
PC3c-ERRα (ERRα), bone nodule number was increased but not significantly compared to PC3c-CT (CT). (C) Confirming mouse calvaria 
results, co-cultures of PC3-ERRα (ERRα) or PC3-CT (CT) cells with the MC3T3-E1 osteoblastic cell line for 2 weeks stimulated expression 
of osteoblastic markers alp (Alcalin Phosphatase), bsp (bone sialoprotein) and ocn (osteocalcin) (ANOVA, P < 0.0001; Student’s t-tests, 
P = 0.0031; P = 0.0098; P = 0.0017) (D) Expression of rankl mRNA was also higher (ANOVA, P < 0.0001, Student’s t-tests, P = 0.0279) 
while opg expression was not altered. (E) Co-cultures of ACE-1-ERRα (ERRα) or ACE-1-CT (CT) cells with the MC3T3-E1 osteoblastic 
cell line for 2 weeks also stimulated bsp and ocn mRNA expression (ANOVA bsp, P = 0.004; Student’s t-tests, P = 0.0003 (ACE-1-CT 
versus ACE-1-ERRα); ANOVA ocn, P = 0.0069; Student’s t-tests, P = 0.0067 (ACE-1-CT versus ACE-1-ERRα) while no regulation was 
observed with ACE-1-AF2 cells (AF2). (F) Expression of rankl and opg mRNA was not regulated. Ob results are representative of two 
independent experiments, each performed in triplicate samples.
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lesions in vivo (Figure 5L, 5N) compared to PC3c-CT 
lesions (Figure 5K, 5M). It is interesting to mention that 
beside tumor mass, vegf-a was also highly expressed in peri-
tumoral cells in PC3c-CT and PC3c-ERRα (Figure 5M, 5N) 
compared to PC3-CT and PC3-ERRα- induced bone lesions 
in vivo (Figure 5C, 5D). This peri-tumoral vegf-a expression 
that probably contributes to the formation of the mixed 
phenotype observed in PC3c cells, was not modulated in 
PC3-ERRα- induced bone lesions in vivo compared to CT. 
Finally, in line with our pre-clinical models, we found that 
VEGF-A positively correlated with ERRα expression levels 
in primary CRPC tumor samples from combined microarray 
datasets GSE1034, GSE6919 and GSE2269 (n = 140, r = 
0.364, P < 0.0001) and in bone metastases (GSE29650, 
GSE41619 and GSE74685) [34–36] (n = 64, r = 0.646, P < 
0.0001) (Table 1; Supplementary Table S1). 
The second factor that was found upregulated by 
ERRα in our human preclinical models is WNT5A, a 
factor also known to stimulate osteoblasts and osteoclasts 
[37] and previously linked to ERRα in osteoblasts 
[38]. Thus, WNT5A expression was higher in ERRα-
overexpressing PC3 cells (PC3-ERRα) compared to 
PC3-CT clones (Figure 6A), and down-regulating ERRα 
levels in PC3 cells with ERRα-SiRNA (pool of three 
sequences) decreased WNT5A expression compared to 
control sequences (Sc, Figure 6B). WNT5A expression 
was also upregulated in PC3-ERRα− versus PC3-CT-
induced bone lesions in vivo (Figure 6C, a versus b). 
XCT-790 treated PC3-ERRα cells also demonstrated 
a down-regulation of WNT5A expression (Figure 6D). 
Stimulation of WNT5A expression by ERRα was also 
confirmed in PC3-ERRα− versus PC3-CT-induced SC 
tumors in vivo (Figure 6E), and in PC3c-ERRα-versus 
PC3c-CT clones in vitro (Figure 6F) as well as in PC3c-
ERRα versus PC3c-CT-induced bone lesions in vivo 
(Figure 6G, a versus b). Notably, WNT5A expression also 
positively correlated with ERRα expression levels in bone 
metastases microarray datasets (GSE29650, GSE41619 
Figure 5: Stimulation of VEGF-A expression in PCa cells by ERRα. (A–B) Visualization of the overexpression of ERRα protein 
expression in tumor by IHC on bone lesions in vivo induced by PC3-ERRα (ERRα)(B) compared PC3-CT (CT)(A). (C–D) Paralleling the 
overexpression of ERRα, VEGF-A expression in tumor was also stimulated in vivo in bone lesions induced by PC3-ERRα (ERRα) (D) 
compared PC3-CT (CT) cells (C). (E) Decreased ERRα protein expression by transfection of three pooled siRNA sequences in parental 
PC3 cells shown by Western blot and (F–G) by real-time RT-PCR for ERRα and VEGF-A expression (Student’s t-tests P = 0.0002; 
P = 0.0027). (H) Decreased VEGF-A mRNA expression was also observed after XCT-790 treatment at 10−6M for 48 h in PC3-ERRα cells 
(Student’s t-tests P = 0.006). (I–J) Real-time RT-PCR was performed on triplicate samples and normalized against the ribosomal protein 
gene L32 to evaluate ERRα (P = 0.0001) and VEGF-A (P = 0.0001) expression within subcutaneous (SC) tumors in vivo (pool of n = 3 
for each condition). (K–N) Similarly, to the PC3 model, IHC revealed that ERRα and VEGF-A protein levels in tumors were increased in 
mixed lesions induced by PC3c-ERRα (ERRα) (L and N concomitantly) compared to PC3c-CT (CT) (K and M concomitantly) in vivo. 
Bar = 200 μm, T: Tumor; OB: osteoblasts; BM: Bone Matrix.
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and GSE74685) (n = 64, r = 0.342, P = 0.00572). Contrary 
to bone metastases specimens, a negative correlation 
with a weak Pearson R value was observed in primary 
CRPC tumor samples from combined microarray datasets 
GSE1034, GSE6919 and GSE2269 (n = 140, r = –0.178, 
P < 0.0001) (Table 1; Supplementary Table S1).
Stimulation of stromal POSTN expression by 
tumor cells overexpressing ERRα 
Given that WNT signaling is known to be recruited 
by the extracellular matrix protein PERIOSTINE (POSTN) 
in the stroma of at least certain tumor types and to 
participate in the steps required for cancer cell colonization 
and tumor progression [8], we next analyzed postn 
expression in our tumor models. By real time PCR, we 
found mouse postn expression up-regulated in PC3-ERRα 
versus PC3-CT SC tumors (Figure 7A). Immunostaining 
confirmed the stimulation of postn in peri-tumoral 
infiltrating cells in PC3-ERRα bone lesions (Figure 7B, 
a versus b), in PC3c-ERRα bone lesions (Figure 7C, a 
versus b) and in peri-tumoral cells in PC3-ERRα SC 
tumor versus PC3-CT SC tumors (Supplementary Figure 
S1A a versus b). Vimentin expression was also addressed 
to show the stromal phenotype of the peri-tumoral cells 
expressing postn (Figure 7Cc). Importantly, ERRα and 
postn expression levels were significantly positively 
correlated in bone metastases specimens (n = 44, r = 0.528, 
P = 0.00023) (Table 1; Supplementary Table S1). A 
positive correlation was also found in adjacent normal 
tissue of primary CRPC tumors (n = 184, r = 0.401, 
P = < 0.0001) confirming the stimulation of POSTN in 
peri-tumoral cells (Table1; Supplementary Table S1). 
Postn has been shown to be stimulated in infiltrating 
stromal cells by factors secreted by breast cancer cells 
such as TGFβ [8, 9]. By real-time PCR, we found 
higher human TGFb1 expression in PC3-ERRα clones 
compared to PC3-CT (Figure 7D). Regulation of TGFb1 
expression by ERRα in PCa cells was also confirmed by 
the lower levels of TGFb1 expression in ERRα-SiRNA 
versus control sequences-transfected PC3 cells (Si 
versus Sc, Figure 7E), in XCT-790 treated PC3-ERRα 
cells versus DMSO (Figure 7F) and by its stimulation in 
PC3-ERRα versus PC3-CT SC tumors in vivo (Figure 7G). 
Immunohistochemistry also confirmed higher TGFb1 
staining in tumor cells in PC3-ERRα (Figure 7Hb) 
compared to PC3-CT-induced (Figure 7Ha) bone lesions 
in vivo and in PC3c-ERRα (Supplementary Figure S1Bb) 
compared to PC3c-CT-induced bone lesions in vivo 
(Supplementary Figure S1Ba). Finally, ERRα and TGFb1 
expression levels were significantly positively correlated 
in primary CRPC tumor samples (n = 140, r = 0.684, 
Figure 6: Stimulation of WNT5A expression in PCa cells by ERRα. (A) Assessment of WNT5A expression by real-time RT-PCR 
on triplicate samples and normalized against the ribosomal protein gene L32. WNT5A (Student’s t-tests P = 0.0305) was higher in PC3-
ERRα versus PC3-CT (CT) cells in vitro. (B) WNT5A (Student’s t-tests P = 0.0007) mRNA expression was decreased in Si-ERRα (pooled 
of three SiRNA sequences) transfected cells compared to control-transfected (Sc) cells. (C) Paralleling the overexpression of ERRα, 
WNT5A protein level expression was also stimulated in tumor in vivo in bone lesions induced by PC3-ERRα (ERRα)(b) compared PC3-
CT (CT) cells (a). (D) Decreased WNT5A mRNA expression was also observed after XCT-790 treatment at 10-6M for 48 h in PC3-ERRα 
cells (Student’s t-tests P = 0.0077). (E) By real-time RT-PCR, we also found WNT5A mRNA expression (Student’s t-tests P = 0.0001) 
increased in PC3-ERRα SC tumors in vivo compared to PC3-CT SC tumors (F) WNT5A (Student’s t-tests P = 0.0026) mRNA expression 
was also upregulated in the PC3c-ERRα ((ERRα(c)) clone compared to the PC3c-CT (CT(c)) in vitro and (G) in tumor in vivo in bone 
lesions induced by PC3c-ERRα (ERRα)(b) compared PC3c-CT (CT) cells (a). Bar = 200 μm, T: Tumor; OB: osteoblasts; BM: Bone Matrix. 
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P = < 0.0001) (Table 1; Supplementary Table S1). On the 
contrary, no significant correlation was observed in bone 
metastases (Table 1; Supplementary Table S1). The data 
suggest that the upregulation of stromal cell POSTN may 
be the initial step through which ERRα induces rapid bone 
lesion progression. 
 DISCUSSION
Our findings indicate that ERRα is a stimulator 
of prostate cancer cell progression in bone. In addition 
to confirming the regulation of the previously identified 
ERRα-regulated gene, VEGF-A [30] we identified WNT5A 
and TGFb1 as new ERRα-regulated genes. Together with 
our observation that ERRα expression is higher in CRPC 
patients with bone metastases than without, and that ERRα 
in PCa alters molecular signaling in the stroma via the 
regulation of POSTN expression in infiltrating fibroblasts 
[10], our data provide new mechanistic insights into 
ERRα-regulated pathways mediating PCa progression in 
bone. 
ERRα-positive prostate tumors have been associated 
with more invasive disease and a higher risk of recurrence 
[18]. For example, ERRα immunoreactivity score has been 
linked with Gleason scores [18]. ERRα was also recently 
associated with hypoxia adaptation in PCa cells (AR+ 
(LNCaP) and AR-(PC3) pre-clinical models), suggesting 
that ERRα might be involved in advanced progression 
of PCa [19]. Advanced PCa has a propensity of 90% to 
metastasize to bone, of 25% to metastasize to liver and to 
develop CRPC, all of which are associated with poor five-
year survival rate [2]. 
Since we had shown that ERRα may be involved 
in bone metastases from breast cancer [22] that prompted 
us to determine if and how ERRα could contribute to 
malignant growth of PCa in bone. Interestingly, ERRα 
stimulation of PCa-induced bone lesion progression is 
different from what we observed in breast cancer [22]. 
ERRα plays a dual role in the progression of breast cancer 
-by promoting local tumor growth but by decreasing 
osteolytic lesions in bone, the latter due to the inhibition 
of osteoclast differentiation. The opposite activity of 
ERRα in PCa versus breast cancer on bone resorbing-cells 
may explain the differences in tumor progression in bone 
between breast and prostate cancers [22] and suggests 
distinct clinical management of prostate versus breast 
cancer patients with bone metastases. 
ERRα expression levels in primary tumors and 
bone metastases associated with PCa patients correlated 
well with our results in three CRPC preclinical mouse 
models. At the cellular level, we found that ERRα directly 
stimulates both osteoclasts and osteoblasts, as well as 
factors in PCa cells thought to stimulate osteoclasts and 
osteoblasts, i.e., VEGF-A [33] [39]; WNT5A [37, 40, 
41] and TGFb1 [1, 6, 42] (Figure  8, pathways 1 and 2). 
Notably, all these factors were also found to correlate 
Table 1: Meta-analysis using public datasets showing correlation between ERRα and VEGFA, 
WNT5A, POSTN and TGFb1 expression levels in bone metastases (GSE29650, GSE41619 and 
GSE74685) and/or in primary CRPC tumor (GSE1034, GSE6919 and GSE2269)
Number of samples (N)
Genes names Database Correlations Primary tumour Bone Metastases
VEGFA/ERRA
GSE21034/ GSE6919/ GSE32269 Pearson R = 0.364 
P = 0.00001
140 CRPC N/A
GSE29650/ GSE41619/GSE74685 Pearson R = 0.646 
P = 0.000001
N/A 64
WNT5A/ERRA
GSE21034/ GSE6919/ GSE32269 Pearson R = −0.178
P = 0.035
140 CRPC N/A
GSE29650/ GSE41619/GSE74685 Pearson R = 0.342
P = 0.00572
N/A 64
POSTN/ERRA
GSE21034/ GSE6919/ GSE32269 Pearson R = 0.401
P = 0.000001
184 in adjacent 
normal tissue
N/A
GSE29650/ GSE41619 Pearson R = 0.528 
P = 0.00023
N/A 44
TGFb1/ERRA
GSE21034/ GSE6919/ GSE32269 Pearson R = 0.684
P = 0.000001
140 CRPC N/A
GSE29650/ GSE41619 Pearson R = −0.365
NS
N/A 14
To obtain z-scores, normalized data were log
2
 transformed and calculated by subtracting the population mean from individual 
expression values for each gene and then dividing the difference by the population standard deviation. Correlation scores 
were calculated using the Pearson correlation coefficient. P-values less than 0.05 were considered statistically significant.
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with ERRα expression in our meta-analysis studies of 
human PCa datasets.
Previously, WNT11 was shown to be regulated by 
ERRα in PCa cells and implicated in cancer cell invasion 
[43]. Our data on WNT5A and ERRα expression in 
both in vivo and in vitro experiments and meta-analysis 
of human PCa datasets reinforces the link between 
ERRα activity and Wnt signaling. Interestingly, analysis 
of circulating tumor cells (CTC) from patients had 
indicate that WNT5A is activated, in keeping with a role 
for WNT5A in cell polarization and cancer cell invasion 
[44, 45, 46]. Indeed, analysis of CTCs from patients 
progressing on AR inhibitor compared with untreated case 
indicates activation of WNT5A [46]. Moreover, Miyamoto 
D et al. show that ectopic expression of WNT5A inhibits 
the anti-proliferative effect of AR inhibition suggesting 
that it may participate in the acquisition of resistance 
to androgen deprivation and to treatment failure [46]. 
However, WNT5A has variously been described as a pro 
or an inhibitor of tumor growth in bone [47, 48]. Our 
results suggest that ERRα-mediated WNT5A is associated 
with advanced PCa metastatic disease in bone, but to fully 
understand the molecular mechanisms and determine 
direct versus indirect regulation by ERRα in tumor 
cells, additional studies are required. Nevertheless, the 
identification of WNT5A as an ERRα-regulated gene may 
represent implications for its potential use as a prognostic 
marker in prostate cancer. 
With respect to PCa-induced osteolysis, we found 
that rankl expression was stimulated in MC3T3-E1 cells 
co-cultured with PC3-ERRα but not with the ACE-1 
cell model, which is a mixed lesion model, whether or 
not ERRα levels were modified in the latter. These data 
suggest indirect regulatory effects on osteoclasts that 
participate in the resorption observed in bone lesions in 
animals bearing ERRα osteolytic tumors but not mixed 
Figure 7: Regulation of stromal postn by ERRα. (A) Assessment of the mouse postn expression by real-time RT-PCR on triplicate 
samples and normalized against the mouse ribosomal protein gene L32. Real-time RT-PCR showed increased postn mRNA expression 
(Student’s t-tests P = 0.0026) in PC3-ERRα-induced SC tumors in vivo. (B) Increased expression of postn in peri-tumoral and infiltrating 
fibroblasts was visualized by IHC on PC3-ERRα-induced bone lesions (b) compared to PC3-CT (a). (C) Similarly, postn protein was 
upregulated in the infiltrating fibroblasts in vivo in bone lesions induced by PC3c-ERRα (ERRα)(b) compared PC3c-CT (CT) cells (a). 
Vimentin antibody was used to show the fibroblastic type of the postn expressing cells (c) (D) Real-time RT-PCR showed that TGFb1 mRNA 
expression (Student’s t-tests P = 0.0246) was higher in PC3-ERRα versus PC3-CT (CT) cells in vitro while (E) TGFb1 (Student’s t-tests 
P = 0.022) mRNA expression was decreased in Si-ERRα (pooled of three sequences) transfected cells compared to control-transfected 
(Sc) cells. (F) Real-time RT-PCR also showed decreased TGFb1 mRNA expression (Student’s t-tests P = 0.0033) in XCT790 treated 
PC3-ERRα cells and (G) increased TGFb1 mRNA expression (Student’s t-tests P = 0.0002) in PC3-ERRα-induced SC tumors in vivo. 
(H) TGFb1 staining was higher in PC3-ERRα (b) compared to PC3-CT (a) in tumor-induced bone lesions in vivo. Bar = 200 µm. T: Tumor; 
OB: osteoblasts; BM: Bone Matrix; IF: infiltrating fibroblasts. 
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lesions (Figure  8, pathway 3). 
Our data suggest that ERRα may also have an 
impact on the stromal microenvironment. The reciprocal 
interaction between cancer cells and tissue-specific stroma 
is known to be critical for primary and metastatic tumor 
growth progression and POSTN is one of the extracellular 
matrix molecules known to participate in tumor 
proliferation and invasion when secreted from stromal 
cells infiltrating tumors [8, 10, 11]. Here, we confirm that 
postn is not only expressed in the stromal cells infiltrating 
tumors of bone xenografts but also in orthotopic PCa 
xenografts [10]. However, we also show for the first time 
that mouse postn expression can be stimulated by PCa 
cells overexpressing ERRα in bone and in SC tumors 
in vivo. Our data also suggest that ERRα may participate 
in the initial expansion of cancer cells by regulating the 
extracellular matrix component postn in stromal cells 
infiltrating tumors at least in part through the regulation of 
TGFb1 in prostate cancer cells (Figure 8, pathway 4) [8]. 
The link between ERRα/POSTN in the clinical models was 
confirmed by our meta-analyses of bone metastases and in 
tumor adjacent tissues in primary tumors, which suggests 
that POSTN may constitute a new prognostic marker in 
association with ERRα. The data also suggest that this 
is may be the initial step by which ERRα induces rapid 
bone lesion progression. Consequently, targeting the tumor 
microenvironment may also constitute a new therapeutic 
approach for prostate cancer patients with high levels of 
ERRα [49]
Very recently, the ERRα coactivator PGC1α has 
been described as a suppressor of PCa metastasis [50]. 
PGC1α is expressed at very low levels (i.e., CT: 33) in 
our PC3, PC3c models, suggesting that the ERRα-PGC1α 
mechanisms described by Torrano et al. are unlikely 
to occur in these models. Taken together, these data 
suggest that ERRα is a suppressor when PGC1α is highly 
expressed and as an activator when PGC1α expression is 
low, in turn strongly suggesting that, depending on the 
expression of ERRα cofactors in PCa cells, ERRα can 
have opposite activities. Thus, it will be important to take 
into account not only the expression of ERRα but also its 
cofactors in tumors specimens.
In conclusion, we report for the first time on the 
involvement of ERRα in the steps of PCa initiation 
and tumor progression in bone, which results from 
ERRα modifications of signaling molecules and the 
microenvironment. Our findings contribute to a new 
understanding of mechanisms underlying the overall 
negative clinical outcome associated with ERRα in prostate 
cancer and provide a rationale for the investigation of ERRα 
as a therapeutic target to treat primary prostate cancers and 
their associated bone metastases. 
Figure 8: Schematic diagram showing ERRα pathways that can mediate tumor progression in bone. Pathway 1: Increased 
expression of pro-resorption factors (VEGF-A, WNT5A, TGFβ1) in PCa tumors overexpressing ERRα leads to direct stimulation of Oc 
formation. Pathway 2: Increased expression of pro-osteoblastic factors (VEGF-A, WNT5A, TGFβ1) in PCa tumors overexpressing ERRα 
that leads to direct stimulation of Ob formation. Pathway 3: Indirect stimulation of osteoclasts through osteoblasts (via the regulation of rankl 
in Ob for the osteolytic model). Pathway 4: Stimulation of the metastatic niche through the stimulation of postn in fibroblasts infiltrating 
tumors by TGFβ1 secreted by tumor cells. Ob: osteoblast; Oc: osteoclast; direct signaling (in green), indirect signaling (in orange). 
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MATERIALS AND METHODS
Ethics approval
SCID male mice were purchased from Charles River 
and handled according to the French Ministerial Decree 
No.87-848 of 19 October 1987. Experimental protocols 
were approved by the Institutional Animal Care and Use 
Committee at the Université Lyon-1 (France) (CEEA-55 
Comité d’Ethique en Expérimentation Animale DR2014-
32). Studies involving human primary prostate tumors 
were carried out according to the principles embodied in 
the Declaration of Helsinki. 
PCa patient primary and bone metastases 
specimens for IHC 
Autopsy files (dating from 1991 to 1998) from 
the Department of Pathology (Tumor Tissue Bank, 
Centre Hospitalier Universitaire de Liège, Belgium) 
were screened for diagnosis of disseminated prostate 
cancer with histologically proven bone metastases [51]. 
For immunohistochemistry (IHC) analysis, we selected 
a prostate cancer patient who died with disseminated 
disease, including bone metastases. We retrieved patient 
slides and their clinical history. Tumors were fixed and 
paraffin-embedded.
Meta-analysis
For correlation analysis in clinical samples, gene 
expression data and corresponding clinical annotations for 
previously published datasets on normal prostate tissue, 
adjacent prostate tissue, primary and bone metastases 
were downloaded from the Gene-Expression-Omnibus 
(GSE6919-GSE29650-GSE32269-GSE41619-GSE21034-
GSE74685) (Supplementary Table S1). To obtain z-scores, 
normalized data were log
2
 transformed and calculated 
by subtracting the population mean from individual 
expression values for each gene and then dividing 
the difference by the population standard deviation. 
Correlation scores were calculated using the Pearson 
correlation coefficient. P-values less than 0.05 were 
considered statistically significant. Statistical significance 
was determined by GraphPad Prism v 5.02 using the two-
sided student t-test. 
Animal studies
SCID male mice, 6 weeks of age, were housed in 
barrier conditions under isolated laminar flow hoods. 
Mice bearing tumor xenografts were closely monitored 
for established signs of distress and discomfort and were 
humanely euthanized.
PC3 cells induce osteolytic lesions, PC3c cells 
induce mixed lesions with lytic and osteoblastic regions in 
the bone marrow cavity [28] while ACE-1 mainly induce 
lytic lesions in the bone marrow cavity and osteoblastic 
region outside the bone (spicules) [29].
Intra-osseous tumor xenograft experiments were 
performed as previously described [28] as for technical 
reason, we could not obtain bone lesions after intra-
arterial and intra-cardiac injections. PC3, PC3c and ACE-
1 cells (6 × 105 in 15µL PBS) were injected in the bone 
marrow cavity [28]. Mice were sacrificed after 3 weeks 
(PC3 and ACE-1) and 6 weeks (PC3c). Radiographs 
(LifeRay HM Plus, Ferrania) of animals were taken at 
that time after inoculation using X-ray (MX-20; Faxitron 
X-ray Corporation). Animals were sacrificed, hind limbs 
were collected for histology and histomorphometrics 
analyses. The bone lesion surface, that includes lytic and 
osteoblastic regions, was measured using the computerized 
image analysis system MorphoExpert (Exploranova). The 
extent of bone lesions for each animal was expressed 
in mm2. Tibiae were scanned using microcomputed 
tomography (Skyscan1174, Skyscan) with an 8.1 µM 
voxel size and an X-ray tube (50 kV; 80 µA) with 0.5 µm 
aluminum filter. Three-dimensional reconstructions and 
rendering were performed using the manufacturer’s suite 
(Respectively, NRecon&CTVox, and Skyscan). Bone 
Volume/Tissue Volume: (%BV/TV) includes residual 
trabecular and remaining cortical bone for PC3 and ACE-
1 models, plus new bone formation into the bone marrow 
cavity for PC3c model. For the ACE-1 model, since the 
osteoblastic lesions is outside the cortical bone, the percent 
(%) of extra-new bone spicules formation (only spicules 
surface) with respect to total volume (trabecular, cortical 
and spicule) (for the ACE model) were quantified. %BV/
TV and % of extra-new bone spicules formation were 
carried out with CTAn (version 1.9, Skyscan) and CTVol 
(version 2.0, Skyscan) software. Dissected bones were 
then processed for histological and histomorphometric 
analysis (tumor burden-to-soft tissue volume (%TB/STV)) 
and TRAP-positive trabecular bone surface (Oc.S) to the 
total bone surface (BS) as described previously for the 
PC3 model [22]. Results were plotted as the mean ± SD. 
Subcutaneous injections of PC3 cells (106 in 100 µl 
PBS) were also performed in 6- to 8-week-old SCID mice. 
Mice were sacrificed after 6 weeks and tumors were fixed 
and embedded in paraffin. 
Cell lines and transfection
The PC3 cell line was obtained from the American 
Type Culture Collection (ATCC) (cell line authentication 
was performed). The PC3c cells, a subculture cell line of 
PC3 was isolated in our laboratory in vitro after single 
cell population culture. Consequently to spontaneous 
derivation of the cells, we finally obtained a subculture 
cell line named PC3c which was chosen based on its 
epithelial phenotype [28]. Osteoprotegerin (OPG) and 
endothelin-1 (ET1) are highly expressed by PC3c while 
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dikkopf-1 (DKK1) expression is decreased. Finally, PC3c 
highly expressed bone associated markers osteopontin, 
Runx2, alkalin phosphatase, bone sialoprotein and 
produced mineralized matrix in vitro in osteogenic 
conditions showing a strong osteomimetism phenotype of 
PC3c cells compared to PC3 [28]. ACE-1 were obtained 
from Dr T Rosol [29]. PC3 and ACE-1 stably transfected 
clones were routinely cultured in F12K (Gibco/Life 
Technologies) and PC3c clones were cultured in DMEM. 
All cultures were supplemented with 10% (v/v) fetal 
bovine serum (Perbio/Thermo Scientific) and 1% (v/v) 
penicillin/streptomycin (Life technologies) at 37°C in a 
5% CO
2
 incubator. 
Human ERRα cDNA (ERRα) and the dominant 
negative form mutated into the co-activator domain 
AF2 (AF2) was obtained previously [22]. Cells were 
cultured under clonal selection for 4 weeks in the 
presence of puromycin (1 μg/mL) (Life Technologies). 
PC3 cells were also transfected (100 pmol) with 
ERRα-siRNA sequences specific to human (ON-
TARGET plus Human ESRRA SMART pool of 
three sequences: GGCCUUCGCUGAGGACUUA / 
GCGAGAGGAGUAUGUUCUA/GGGUGGGCAUGC 
UCAAGGA) and control sequences (ON-TARGET 
plus Human Non-targeting pool of three sequences: 
UGGUUUACAUGUCGACUAA/UGGUUUACAUGUU 
GUGUGA/UGGUUUACAUGUUUUCCUA) (Dharmacon) 
and mRNA were extracted at 72 h after transfection. 
Conditioned medium from PC3 and PC3c clones (used 
on primary calvaria cells culture) and PC3 parental cells 
treated with the XCT-790 at 10-6 M (Sigma) was obtained 
after 48 hours in α-MEM supplemented with 0.5% of 
serum, then filter sterilized and proteins quantified to use 
equal concentration of proteins for each conditions (25 μg). 
Dimethyl sulfoxide (DMSO) was used as control (CT). 
PC3-ERRα cells (pool of three clones) were treated with 
the inverse agonist XCT-790 at 10-6 M (Sigma) for 48 h. 
DMSO was used as control (CT).
Osteoclastogenesis assay 
Bone marrow cells from 6-week-old OF1 male mice 
were cultured for 7 days as previously described [22]. 
Pools of PC3-CT/PC3-ERRα clones or PC3c-CT/PC3c-
ERRα or ACE-1-CT/ ERRα /AF2 were plated (104 cells) 
on day 1 on bone marrow cells culture in presence of rankl 
and m-csf. Mature osteoclasts were stained for TRAP 
activity (Sigma-Aldrich). Multinucleated TRAP-positive 
cells containing three or more nuclei were counted as 
osteoclasts. Results were plotted as the mean ± SD of three 
wells for each condition and were representative of two 
independent experiments. 
Osteoblastogenesis assay 
Cells were enzymatically isolated from the calvaria 
as described previously [31]. Mouse calvaria cells were 
continuously exposed (21 days) to conditioned medium 
isolated from cultures of PC3 pooled clones or PC3c 
clones. Wells were stained with von Kossa stain for ALP 
and bone nodules were counted on a grid [31]. Results 
were plotted as the mean number of nodules ± SD of 
three wells and were representative of two independent 
experiments. The murine osteoblastic MC3T3-E1 cell 
line was cultured for 2 weeks with pooled PC3-CT versus 
PC3-ERRα clones or ACE-1-CT/ERRα/AF2 that were 
plated (104 cells) on day 1 for 2 weeks. mRNA were then 
extracted and osteoblastic markers expression addressed 
by real-time PCR.
 Immunohistochemistry
Tibia bearing metastases were fixed and embedded 
in paraffin. IHC analysis was performed by incubating 
sections overnight with rabbit monoclonal against 
human and mouse anti-VEGF-A (1/50) (Abcam), rabbit 
polyclonal antibodies against human and mouse WNT5a 
(1/70)(Abcam), goat anti-mouse postn (1/200)(R&D), 
mouse monoclonal anti- human/mouse TGFb1 (1/40) 
(R&D), rabbit polyclonal anti-mouse vimentin(1/50)
(Biovision) and mouse monoclonal anti-human/mouse 
ERRα antibody (1/50)(Santa Cruz) [22]. Sections were 
then incubated with HRP-conjugated anti-mouse (Dako), 
anti-rabbit (Dako) or the anti-goat (Jackson) antibodies 
for 1hour and stained using 3,3′-diaminobenzidine 
(Dako). Counterstaining was performed using Mayer’s 
hematoxylin (Merck).
Immunoblotting
Protein extraction and immunoblotting were 
performed as described previously [22]. As the mouse 
monoclonal anti-human/mouse ERRα antibody (Santa Cruz) 
did not work in Western-blots, we used a rabbit monoclonal 
antibody against ERRα (Epitomics) (1:400) [22] and a rabbit 
polyclonal antibody against GAPDH (Abcam) (1:10,000) 
(Amersham) as a protein loading control. 
Real time RT-PCR
Total RNA was extracted with Trizol reagent 
(Life Technologies) and 2 μg was reverse-transcribed 
using Superscript™II (Life Technologies) [22]. Real-
time PCR was performed on a Mastercycler-ep-Realplex 
(Eppendorf) with primers specific to human and mouse 
genes (Supplementary Table S2) using Quantifast SYBR 
Green (Life Technologies). PCR was carried out according 
to the manufacturer’s instructions. Melting curve analysis 
was used to verify that a single peak was obtained for each 
product with a 95–100% PCR efficiency (Roche software). 
Relative gene expression levels were normalized according 
to the Ct value of the housekeeping gene encoding the 
ribosomal protein L32 and results were expressed as fold 
differences equal to 2-∆∆Ct. 
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Statistical analysis
Statistical analysis was performed using GraphPad 
Prism software (San Diego,USA). Pairwise comparisons 
were tested using a non-parametric Mann-Whitney U test for 
bone metastases. In vitro data were analyzed using ANOVA 
and Student’s t-tests to assess the differences between 
groups. Results of P < 0.05 were considered significant.
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